Subgroup analyses revealed heterogeneous effects among patients with different APACHE scores, suggesting that early prophylactic activation of IRF1 may preferentially benefit patients with severe sepsis but not those with mild sepsis (Fig. 4E). This evidence concerns the gene IRF1 and Sepsis.